Refractory Multiple Myeloma Case 1 Monitoring PostASCT Blood Testing Other Monitoring After Initial Therapy Case 1 cont Assessment at Relapse Symptomatic First Relapse Cytogenetic Testing at Relapse ID: 556975
Download Presentation The PPT/PDF document "Selecting Therapy for Relapsed/" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Selecting Therapy for Relapsed/Refractory Multiple MyelomaSlide2Slide3
Case #1Slide4
Monitoring Post-ASCTBlood TestingSlide5
Other Monitoring After Initial TherapySlide6
Case #1 (cont)Slide7
Assessment at RelapseSymptomatic First RelapseSlide8
Cytogenetic Testing at RelapseSlide9
Therapy Selection ConsiderationsSlide10
Recent Phase 3 Trials in R/R MMSlide11
ASPIRE
Len/Dex ± CarfilzomibSlide12
TOURMALINE-MM1Ixazomib + Len/Dex vs Placebo + Len/DexSlide13
ELOQUENT-2
Len/Dex ± ElotuzumabSlide14
POLLUX
Len/Dex ± DaratumumabSlide15
CASTORBor/Dex ± DaratumumabSlide16
ENDEAVOR Carfilzomib/Dex vs Bor/DexSlide17
PANORAMA-1Panobinostat/Bor/Dex vs Placebo/Bor/DexSlide18
Recent Phase 3 Trials in R/R MMSlide19
Other Issues to ConsiderSlide20
Special Safety ConsiderationsSlide21
Role of Second ASCT in First RelapseSlide22
Select Emerging Agents in MMSlide23
Key TakeawaysSlide24
AbbreviationsSlide25
Abbreviations (cont)Slide26
Abbreviations (cont)